• Something wrong with this record ?

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis

D. Cadavid, JA. Cohen, MS. Freedman, MD. Goldman, HP. Hartung, E. Havrdova, D. Jeffery, R. Kapoor, A. Miller, F. Sellebjerg, D. Kinch, S. Lee, S. Shang, D. Mikol,

. 2017 ; 23 (1) : 94-105. [pub] 20160711

Language English Country Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18011276

BACKGROUND: The Expanded Disability Status Scale (EDSS) has wide scientific and regulatory precedent but limited ability to detect clinically relevant disability progression in secondary progressive multiple sclerosis (SPMS) patients, partly due to a lack of meaningful measurement of short-distance ambulatory and upper-extremity function. OBJECTIVE: To present a rationale for a composite endpoint adding the timed 25-foot walk (T25FW) and 9-Hole Peg Test (9HPT) to EDSS for SPMS disability progression assessment. METHODS: Using the International Multiple Sclerosis Secondary Progressive Avonex Clinical Trial (IMPACT) placebo arm ( n = 215) data, we analyzed disability progression using a novel progression endpoint, "EDSS-Plus," defined as progression on ⩾1 of 3 components (EDSS, T25FW, and/or 9HPT) confirmed ⩾24 weeks apart and with a ⩾20% minimum threshold change for T25FW and 9HPT. RESULTS: Over 2 years, subjects classified as T25FW, 9HPT (dominant hand), or 9HPT (non-dominant hand) progressors worsened on average by 103.4%, 69.0%, and 59.2%, respectively, while non-progressors' times remained largely unchanged. Using EDSS-Plus, 59.5% of the patients had 24-week confirmed disability progression versus 24.7% (EDSS), 41.9% (T25FW), and 34.4% (9HPT (either hand)) on each component alone. CONCLUSION: The 24-week confirmed minimum worsening of ⩾20% for T25FW and 9HPT clearly separates SPMS progressors from non-progressors. We propose that EDSS-Plus may represent an improved endpoint to identify SPMS disability progression.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011276
003      
CZ-PrNML
005      
20180404142707.0
007      
ta
008      
180404s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/1352458516638941 $2 doi
035    __
$a (PubMed)27003945
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Cadavid, Diego $u Biogen, Cambridge, MA, USA.
245    14
$a The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis / $c D. Cadavid, JA. Cohen, MS. Freedman, MD. Goldman, HP. Hartung, E. Havrdova, D. Jeffery, R. Kapoor, A. Miller, F. Sellebjerg, D. Kinch, S. Lee, S. Shang, D. Mikol,
520    9_
$a BACKGROUND: The Expanded Disability Status Scale (EDSS) has wide scientific and regulatory precedent but limited ability to detect clinically relevant disability progression in secondary progressive multiple sclerosis (SPMS) patients, partly due to a lack of meaningful measurement of short-distance ambulatory and upper-extremity function. OBJECTIVE: To present a rationale for a composite endpoint adding the timed 25-foot walk (T25FW) and 9-Hole Peg Test (9HPT) to EDSS for SPMS disability progression assessment. METHODS: Using the International Multiple Sclerosis Secondary Progressive Avonex Clinical Trial (IMPACT) placebo arm ( n = 215) data, we analyzed disability progression using a novel progression endpoint, "EDSS-Plus," defined as progression on ⩾1 of 3 components (EDSS, T25FW, and/or 9HPT) confirmed ⩾24 weeks apart and with a ⩾20% minimum threshold change for T25FW and 9HPT. RESULTS: Over 2 years, subjects classified as T25FW, 9HPT (dominant hand), or 9HPT (non-dominant hand) progressors worsened on average by 103.4%, 69.0%, and 59.2%, respectively, while non-progressors' times remained largely unchanged. Using EDSS-Plus, 59.5% of the patients had 24-week confirmed disability progression versus 24.7% (EDSS), 41.9% (T25FW), and 34.4% (9HPT (either hand)) on each component alone. CONCLUSION: The 24-week confirmed minimum worsening of ⩾20% for T25FW and 9HPT clearly separates SPMS progressors from non-progressors. We propose that EDSS-Plus may represent an improved endpoint to identify SPMS disability progression.
650    _2
$a dospělí $7 D000328
650    _2
$a posuzování pracovní neschopnosti $7 D004185
650    _2
$a postižení $x rehabilitace $7 D006233
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a chronicko-progresivní roztroušená skleróza $x diagnóza $x patofyziologie $7 D020528
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a časové faktory $7 D013997
650    _2
$a horní končetina $x patofyziologie $7 D034941
650    _2
$a chůze $x fyziologie $7 D016138
655    _2
$a časopisecké články $7 D016428
700    1_
$a Cohen, Jeffrey A $u Cleveland Clinic, Cleveland, OH, USA.
700    1_
$a Freedman, Mark S $u University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
700    1_
$a Goldman, Myla D $u University of Virginia, Charlottesville, VA, USA.
700    1_
$a Hartung, Hans-Peter $u Department of Neurology, Medical Faculty, Heinrich- Heine University, Düsseldorf, Germany.
700    1_
$a Havrdova, Eva $u Charles University in Prague, Prague, Czech Republic.
700    1_
$a Jeffery, Douglas $u Piedmont HealthCare, Huntersville, NC, USA.
700    1_
$a Kapoor, Raj $u National Hospital for Neurology and Neurosurgery, London, UK.
700    1_
$a Miller, Aaron $u Icahn School of Medicine at Mount Sinai, New York, NY, USA.
700    1_
$a Sellebjerg, Finn $u Danish Multiple Sclerosis Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
700    1_
$a Kinch, Deborah $u Biogen, Cambridge, MA, USA.
700    1_
$a Lee, Sophia $u Biogen, Cambridge, MA, USA.
700    1_
$a Shang, Shulian $u Biogen, Cambridge, MA, USA.
700    1_
$a Mikol, Daniel $u Biogen, Cambridge, MA, USA.
773    0_
$w MED00006389 $t Multiple sclerosis (Houndmills, Basingstoke, England) $x 1477-0970 $g Roč. 23, č. 1 (2017), s. 94-105
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27003945 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180404142747 $b ABA008
999    __
$a ok $b bmc $g 1288761 $s 1008088
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 23 $c 1 $d 94-105 $e 20160711 $i 1477-0970 $m Multiple sclerosis $n Mult Scler $x MED00006389
LZP    __
$a Pubmed-20180404

Find record

Citation metrics

Archiving options